Maxwell Biosciences Overview
- Founded
- 2016
- Status
- Private
- Employees
- 9
- Latest Deal Type
- Seed
- Latest Deal Amount
- $3.7M
- Investors
- 21
Maxwell Biosciences General Information
Description
Developer of a novel synthetic biomimic drug class intended to target human virus. The company's virucidal drugs mimic natural antimicrobial peptides and destroy a broad range of viruses directly, irreversibly and permanently inactivating the virus itself. Maxwell drug candidates have direct virucidal action against SARS-CoV-2, the COVID-19 virus. Maxwell's drugs have undergone testing and is effective against Herpes Simplex Virus-1 (HSV-1), Chikungunya, Hepatitis B Virus (HBV ), and Influenza.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 3809 Juniper Trace
- Suite 102
- Austin, TX 78738
- United States
Maxwell Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Seed Round | 01-Oct-2020 | $3.7M | 00.00 | Completed | Pre-Clinical Trials | |
| 1. Grant | 0000 | Completed | Pre-Clinical Trials |
Maxwell Biosciences Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a novel synthetic biomimic drug class intended to target human virus. The company's virucidal drugs mimic n
Drug Discovery
Austin, TX
9
As of 2020
00.00
000000000
00.00
0000000
esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
000000000 0000000000
Luçon, France
0
As of 0000
00000
000000 - 000
00000
00000000
tetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
000000000000000
Saint-Amand-Les-Eaux, France
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialMaxwell Biosciences Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Moderna | Venture Capital-Backed | Luçon, France | 0 | 00000 | 000000 - 000 | 00000 |
| 000000000000000 00 | Corporation | Saint-Amand-Les-Eaux, France |
Maxwell Biosciences Executive Team (5)
Maxwell Biosciences Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Annelise Barron Ph.D | Maxwell Biosciences | Co-Founder, Co-Inventor & Board Member | 000 0000 |
| Joshua McClure | Maxwell Biosciences | Co-Founder, Co-Inventor, Chief Executive Officer & Board Member | 000 0000 |
| Robert Neville | Self | Board Member | 000 0000 |
| Stephen Pearse | Yucatan Rock Ventures | Executive Chairman | 000 0000 |
Maxwell Biosciences Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialMaxwell Biosciences Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| 3Rodeo | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Brazos Resources, LP | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
| Campa Investments | Other | Minority | 000 0000 | 000000 0 | |
| Capital Factory | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Catanzaro Family | Other | Minority | 000 0000 | 000000 0 |